Sign In
Last checked at 
21 Apr 2022 10:16
Directors Dealings / Market Share Purchase
Oxford, UK - 21 April 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, today announces that that the Company's Chair & Interim Chief Executive Officer has increased his shareholding in the Company through the purchase of shares.
Dr. Roch Doliveux, Chair & Interim Chief Executive Officer of the Group, has purchased 29,000 ordinary shares of 50p each ("Ordinary Shares") in the Company on 20 April 2022 on the London Stock Exchange at a price of 536.2p. Following this purchase Dr. Roch Doilveux holds 215,459 shares representing 0.224% of the Company.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.
1. | Details of the person discharging material responsibilities/person closely associated
| ||
a. | Name | Roch Doliveux
| |
2. | Reason for the notification
| ||
a. | Position/status | Chair & Interim CEO | |
b. | Initial notification /amendment | Initial notification
| |
3. | Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
| ||
a. | Name | Oxford Biomedica plc
| |
b. | Legal Entity Identifier | 213800S1GVQNXQ15K851
| |
4. | Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||
a. | Description of the financial instrument, type of instrument identification code | Oxford Biomedica plc Ordinary Shares of 50p each
GB00BDFBVT43
| |
b. | Nature of the transaction | Purchase of ordinary shares
| |
c. | Currency | GBP - British Pound
| |
d. | Price(s) and volume(s) |
Price(s)
|
Volume(s) |
£5.36 | 29,000 | ||
|
| ||
e. | Aggregated information · Aggregated volume · Price · Aggregated total
|
29,000
£5.3620 £155,498.00
| |
f. | Date of the transaction | 2022-04-20
| |
g. | Place of the transaction | London Stock Exchange, Main Market (XLON)
| |
-Ends-
For further information, please contact: |
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.
Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com.
Follow the stocks
